Thomas Adams | Cystic Fibrosis: A Multi-Disciplinary Review

Cystic Fibrosis: A Multi-Disciplinary Review Medical Poster (PDF)
Contact: th518246@dal.ca

Resources

1. Quittner AL, Goldbeck L, Abbott J, Duff A, Lambrecht P, Solé A, Tibosch MM, Brucefors AB, Yüksel H, Catastini P, et al. Prevalence of depression and anxiety in patients with cystic fibrosis and parent caregivers: results of The International Depression Epidemiological Study across nine countries. Thorax [Internet]. 2014;69(12):1090-1097. Available from: https://thorax.bmj.com/content/69/12/1090
2. Provincial Health Services Authority. Screening, care & supports [Internet]. Vancouver (BC): Provincial Health Services Authority; [cited 2026 Apr 9]. Available from: https://www.phsa.ca/health-info/cystic-fibrosis/screening-care-supports
3. Morral N, Bertranpetit J, Estivill X, Nunes V, Casals T, Giménez J, et al. The origin of the major cystic fibrosis mutation (ΔF508) in European populations. Nature Genetics. 1994 Jun;7(2):169–75.
4. Henn BM, Cavalli-Sforza LL, Feldman MW. The great human expansion. Proceedings of the National Academy of Sciences [Internet]. 2012 Oct 17;109(44):17758–64. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3497766/
5. Frías J, Ruiz E, Castillo L, García M. The History of Cystic Fibrosis. Open J Pediatr Child Health [Internet]. 2019 [cited 2026 Jan 30];4(1):1-006. Available from: https://www.healthdisgroup.us/articles/OJPCH-4-115.pdf
6. QUINTON PM. Physiological Basis of Cystic Fibrosis: A Historical Perspective. Physiological Reviews. 1999 Jan 1;79(1):S3–22.
7. Davis PB. Cystic Fibrosis Since 1938. American Journal of Respiratory and Critical Care Medicine [Internet]. 2006 Mar;173(5):475–82. Available from: https://www.atsjournals.org/doi/full/10.1164/rccm.200505-840OE
8. Piehler L, Thalemann R, Lehmann C, Thee S, Röhmel J, Syunyaeva Z, Stahl M, Mall MA, Graeber SY. Effects of elexacaftor/tezacaftor/ivacaftor therapy on mental health of patients with cystic fibrosis. Front Pharmacol [Internet]. 2023;14:1179208. Figure 2 available from: https://www.researchgate.net/figure/Effects-of-elexacaftor-tezacaftor-ivacaftor-ETI-on-sweat-chloride-concentration_fig2_370600359
9. Shteinberg M, Haq IJ, Polineni D, Davies JC. Cystic fibrosis. The Lancet [Internet]. 2021 Jun 5;397(10290):2195–211. Available from: https://pubmed.ncbi.nlm.nih.gov/34090606/
10. Ong T, Ramsey BW. Cystic fibrosis: A review. JAMA [Internet]. 2023 Jun 6;329(21):1859–71. Available from: https://jamanetwork.com/journals/jama/article-abstract/2805701
11. Cystic Fibrosis Foundation. Types of CFTR Mutations [Internet]. Cystic Fibrosis Foundation. 2023. Available from: https://www.cff.org/research-clinical-trials/types-cftr-mutations
12. N. Reyne, McCarron A, Cmielewski P, Parsons D, Donnelley M. To bead or not to bead: A review of Pseudomonas aeruginosa lung infection models for cystic fibrosis. Frontiers in Physiology. 2023 Feb 7;14.
13. Lin B, Gong J, Keenan K, Lin F, Lin YC, Mésinèle J, et al. Genome-wide association study of susceptibility to Pseudomonas aeruginosa infection in cystic fibrosis. The European respiratory journal [Internet]. 2024 Jul;64(5):2400062. Available from: https://pubmed.ncbi.nlm.nih.gov/39117430/
14. Martin C, Burgel PR. Carriers of a single CFTR mutation are asymptomatic: an evolving dogma?. European Respiratory Journal. 2020 Sep;56(3):2002645.
15. Miller AC, Comellas AP, Hornick DB, Stoltz DA, Cavanaugh JE, Gerke AK, et al. Cystic Fibrosis Carriers Are at Increased Risk for a Wide Range of Cystic fibrosis-related Conditions. Proceedings of the National Academy of Sciences of the United States of America. 2020 Jan 21;117(3):1621–7.
16. Quittner AL, Abbott J, Georgiopoulos AM, Goldbeck L, Smith B, Hempstead SE, et al. International Committee on Mental Health in Cystic Fibrosis: Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus statements for screening and treating depression and anxiety. Thorax [Internet]. 2015 Oct 9;71(1):26–34. Available from: https://www.cysticfibrosisjournal.com/article/S1569-1993(16)30488-X/pdf
17. Harrigan M, Georgiopoulos AM, Quittner AL, Smith B, Douglas TA. Psychosocial and mental health in cystic fibrosis in the modern era of care: time to evolve. BMJ Open Respiratory Research [Internet]. 2025 Feb 1;12(1):e002606–6. Available from: https://bmjopenrespres.bmj.com/content/12/1/e002606
18. Caiola C, Docherty SL, Relf M, Barroso J. Using an Intersectional Approach to Study the Impact of Social Determinants of Health for African American Mothers Living With HIV. Advances in Nursing Science. 2014;37(4):287–98.
19. Baral PK, Dummer J, Pletzer D, Das SC. Inhaled Antibiotic and Biologic Formulations Targeting Pseudomonas aeruginosa. Pharmaceutics [Internet]. 2026 Jan 26 [cited 2026 Jan 31];18(2):162–2. Available from: https://www.mdpi.com/1999-4923/18/2/162
20. Noah TL, Ivins SS, Abode KA, Stewart PW, Michelson PH, Harris WT, Henry MM, Leigh MW. Inhaled versus systemic antibiotics and airway inflammation in children with cystic fibrosis and Pseudomonas. Pediatr Pulmonol [Internet]. 2010;45(3):281-290. Available from: https://onlinelibrary.wiley.com/doi/10.1002/ppul.21176
21. Fila L, Grandcourtova A, Bilkova A, Drevinek P. Elexacaftor-tezacaftor-ivacaftor in patients with cystic fibrosis ineligible for clinical trials: a 24-week observational study. Front Pharmacol [Internet]. 2023;14:1178009. Available from: https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2023.1178009/full
22. Maia C. New drugs in cystic fibrosis: what has changed in the last decade? [Internet]. ResearchGate; 2022 [cited 2026 Apr 9]. Available from: https://www.researchgate.net/figure/Site-and-mechanism-of-action-of-different-CFTR-modulator-drugs-Source-Reused-with_fig1_360763141
23. Bayerische Staatsbibliothek. Codex latinus monacensis 849 [Internet]. Munich (Germany): Münchener Digitalisierungszentrum; [cited 2026 Apr 9]. Available from: https://www.digitale-sammlungen.de/en/view/bsb00037155?page=4,5

Image Attributions

• Figure 1 from source 23
  Bayerische Staatsbibliothek. Codex latinus monacensis 849 [Internet]. Munich (Germany): Münchener Digitalisierungszentrum; [cited 2026 Apr 9]. Available from: https://www.digitale-sammlungen.de/en/view/bsb00037155?page=4,5
• Figure 2, Figure 3, Figure 9, and Figure 17 from source 7
  Davis PB. Cystic Fibrosis Since 1938. American Journal of Respiratory and Critical Care Medicine [Internet]. 2006 Mar;173(5):475–82. Available from: https://www.atsjournals.org/doi/full/10.1164/rccm.200505-840OE
• Figure 4 from source 3
  Morral N, Bertranpetit J, Estivill X, Nunes V, Casals T, Giménez J, et al. The origin of the major cystic fibrosis mutation (ΔF508) in European populations. Nature Genetics. 1994 Jun;7(2):169–75.
• Figure 5 from source 4
  Henn BM, Cavalli-Sforza LL, Feldman MW. The great human expansion. Proceedings of the National Academy of Sciences [Internet]. 2012 Oct 17;109(44):17758–64. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3497766/
• Figure 6 from source 9
  Shteinberg M, Haq IJ, Polineni D, Davies JC. Cystic fibrosis. The Lancet [Internet]. 2021 Jun 5;397(10290):2195–211. Available from: https://pubmed.ncbi.nlm.nih.gov/34090606/
• Figure 7 from source 10
  Ong T, Ramsey BW. Cystic fibrosis: A review. JAMA [Internet]. 2023 Jun 6;329(21):1859–71. Available from: https://jamanetwork.com/journals/jama/article-abstract/2805701
• Figure 8 from source 15
  Miller AC, Comellas AP, Hornick DB, Stoltz DA, Cavanaugh JE, Gerke AK, et al. Cystic Fibrosis Carriers Are at Increased Risk for a Wide Range of Cystic fibrosis-related Conditions. Proceedings of the National Academy of Sciences of the United States of America. 2020 Jan 21;117(3):1621–7.
• Figure 10 from source 21
  Fila L, Grandcourtova A, Bilkova A, Drevinek P. Elexacaftor-tezacaftor-ivacaftor in patients with cystic fibrosis ineligible for clinical trials: a 24-week observational study. Front Pharmacol [Internet]. 2023;14:1178009. Available from: https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2023.1178009/full
• Figure 11 from source 20
  Noah TL, Ivins SS, Abode KA, Stewart PW, Michelson PH, Harris WT, Henry MM, Leigh MW. Inhaled versus systemic antibiotics and airway inflammation in children with cystic fibrosis and Pseudomonas. Pediatr Pulmonol [Internet]. 2010;45(3):281-290. Available from: https://onlinelibrary.wiley.com/doi/10.1002/ppul.21176
• Figure 12 from source 8
  Piehler L, Thalemann R, Lehmann C, Thee S, Röhmel J, Syunyaeva Z, Stahl M, Mall MA, Graeber SY. Effects of elexacaftor/tezacaftor/ivacaftor therapy on mental health of patients with cystic fibrosis. Front Pharmacol [Internet]. 2023;14:1179208. Figure 2 available from: https://www.researchgate.net/figure/Effects-of-elexacaftor-tezacaftor-ivacaftor-ETI-on-sweat-chloride-concentration_fig2_370600359
• Figure 13 from source 22
  Maia C. New drugs in cystic fibrosis: what has changed in the last decade? [Internet]. ResearchGate; 2022 [cited 2026 Apr 9]. Available from: https://www.researchgate.net/figure/Site-and-mechanism-of-action-of-different-CFTR-modulator-drugs-Source-Reused-with_fig1_360763141
• Figure 14 from source 12
  N. Reyne, McCarron A, Cmielewski P, Parsons D, Donnelley M. To bead or not to bead: A review of Pseudomonas aeruginosa lung infection models for cystic fibrosis. Frontiers in Physiology. 2023 Feb 7;14.
• Figure 15 from source 13
  Lin B, Gong J, Keenan K, Lin F, Lin YC, Mésinèle J, et al. Genome-wide association study of susceptibility to Pseudomonas aeruginosa infection in cystic fibrosis. The European respiratory journal [Internet]. 2024 Jul;64(5):2400062. Available from: https://pubmed.ncbi.nlm.nih.gov/39117430/
• Figure 16 from source 2
  Provincial Health Services Authority. Screening, care & supports [Internet]. Vancouver (BC): Provincial Health Services Authority; [cited 2026 Apr 9]. Available from: https://www.phsa.ca/health-info/cystic-fibrosis/screening-care-supports
• Figure 18 from source 1
  Quittner AL, Goldbeck L, Abbott J, Duff A, Lambrecht P, Solé A, Tibosch MM, Brucefors AB, Yüksel H, Catastini P, et al. Prevalence of depression and anxiety in patients with cystic fibrosis and parent caregivers: results of The International Depression Epidemiological Study across nine countries. Thorax [Internet]. 2014;69(12):1090-1097. Available from: https://thorax.bmj.com/content/69/12/1090

Cystic Fibrosis: A Multi-Disciplinary Review Medical Poster (PDF)

Contact: th518246@dal.ca